P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.
Dharminder Chauhan,Ajita V. Singh,Mugdha Velankar,Teru Hideshima,Huib Ovaa,Celia R. Berkers,Giada Bianchi,Roberto Sitia,Nikhil C. Munshi,Paul G. Richardson,Michael A. Palladino,Kenneth C. Anderson +11 more
TL;DR: The time-kinetics of early events triggered by these two agents in multiple myeloma (MM) cells are examined to suggest that both NPI-0052- and bortezomib-triggered apoptosis is associated with sequential occurrence of proteasome activity.
Journal ArticleDOI
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma
Sarah A. Holstein,Vera J. Suman,Kouros Owzar,Katelyn Santo,Don M. Benson,Thomas C. Shea,Thomas Martin,Margarida Silverman,Luis Isola,Ravi Vij,Bruce D. Cheson,Charles A. Linker,Kenneth C. Anderson,Paul G. Richardson,Philip L. McCarthy +14 more
TL;DR: This study demonstrated the feasibility of performing tandem ASCT/alloSCT in a cooperative group setting and determined that a fludarabine/cyclophosphamide RIC regimen is associated with a very low TRM rate.
Journal ArticleDOI
Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Irene M. Ghobrial,Erica N Boswell,Ranjit Banwait,Tiffany Poon,Amanda Donovan,Stacey Chuma,Janet Kunsman,Diane Warren,Meghan Bagshaw,Kenneth C. Anderson,Paul G. Richardson,Steven P. Treon +11 more
TL;DR: Overall, this combination therapy is very well tolerated and patients who showed an increase in IgM after rituximab in the first 3 months were not deemed as having progressive disease unless they showed evidence of clinical progression.
Journal ArticleDOI
The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma.
Christin B. DeStefano,Steven J. Gibson,Adam S. Sperling,Paul G. Richardson,Irene M. Ghobrial,Clifton C. Mo +5 more
TL;DR: Clonal hematopoiesis (CH) has been shown to correlate with inferior survival in MM due to increased risk of disease progression in patients who are treated with high-dose melphalan without lenalidomide maintenance and could also potentially elevate the risk of secondary MDS and/or AML, cardiovascular events, and venous thromboembolic events.
Journal ArticleDOI
Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results.
Irene M. Ghobrial,Xavier Leleu,Nancy Rubin,Marybeth Nelson,Renee Leduc,Diane Warren,Jana Allen,Sue Lovecchio,Jacob D. Soumerai,Peter Sportelli,Robert Birch,Craig Henderson,Steven P. Treon,Paul G. Richardson,Kenneth C. Anderson +14 more
TL;DR: Oral perifosine as monotherapy has been well tolerated and demonstrates encouraging activity achieving PR + MR in 34%, and/or stabilization of disease in 66% of evaluable patients with relapsed WM.